Glomerular disease, be it primary or secondary, occurring in the setting of systemic autoimmune
diseases, infections, drugs, or malignancy, affects individuals of all ages. In most kidney …

The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the
Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is …

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies
Conference on glomerular diseases in November 2017. The conference focused on the …

In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative
brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO …

Renal ischemia and reperfusion (I/R) injury is the major cause of acute renal failure and
may also be involved in the development and progression of some forms of chronic kidney …

Over the past year, and for the first time ever, the US Food and Drug Administration approved
2 drugs specifically for the treatment of lupus nephritis (LN). As the lupus community works …

Glucocorticoids therapy has greatly improved the outcome of lupus nephritis patients. Since
their discovery, their adverse effects have counterbalanced their beneficial anti-inflammatory …

Background Clinical distinction between patients with lupus nephritis who have active
inflammation or chronic kidney damage is challenging. Studies have shown soluble CD163, …

Objective: To develop a score to predict the need for intensive care unit (ICU) admission in
Covid-19. Materials and methods: We assessed patients admitted to a Covid-19 center in …

To the editor: We read the report by Tuschen et al. of a 42-year-old woman with a previous
diagnosis of systemic lupus erythematosus (SLE) and class V lupus nephritis (LN) that …